Contact Us

Clinical Trials

Liquid Tissue®-SRM technology enables mass spectrometry measurement in FFPE tissue of proteins in tumor signaling networks. Expression Pathology is developing clinical assays, such as for targeted anti-EGFR drug selection, and offers a broad menu of its Liquid Tissue®-SRM Assays performed under Good Laboratory Practice (GLP) standards for clinical drug development.

This rapidly expanding menu of assays includes a wide range proteins such as EGFR, HER3, IGF-1R, cMET, cSRC, DR5, MEK, and ERK. The assays may be able to provide information such as the presence of protein drug targets, or which biological pathways are up or down regulated in tumors. This may help aid prognosis and drug selection.